Conceptual visualization. Not a photograph of an experiment and not a figure from a paper. Don't Die Now
Optogenetics
Light-sensitive tools are used in neuroscience and, in specific trials, in retinal disease. That is not evidence of a longer human life. Human lifespan extension is not established here. A disease approval is not an anti-aging approval.
Latest discoveries
Optogenetic vision restoration: citation on file
Gene Therapy published Naoyuki Nakada’s article on 2 September 2026. Crossref has the record. The article’s results are not restated.
A phase 1 photoswitch trial in advanced retinitis pigmentosa
Nature Medicine reported a first-in-human safety study of KIO-301 in six people with advanced retinitis pigmentosa. It is not a longevity study.
Featured research
Optogenetic vision restoration: translational barriers and emerging therapeutic strategies
Nakada N
Crossref confirms the title, the author Naoyuki Nakada, the journal Gene Therapy, and the date 2 September 2026. Results and translational claims from the article are not restated.
Bibliographic verification only.
Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Casson RJ, Daniels E, Barras CD, Dwyer A, Strem BM, Wykoff CC, Gregorio-King C, Schuh C, Kramer RH, Van Gelder RN
Six participants with advanced retinitis pigmentosa received KIO-301 in 12 eyes. The abstract reports no serious adverse events and no dose-limiting toxicities. It says ocular adverse events were mild and procedure-related. Exploratory measures of light perception and functional vision varied. The registry named in the abstract is NCT05282953. This is a photoswitch study in a retinal disease, not a human longevity trial.
Small, open-label, nonrandomized phase 1. The primary window in the abstract is 30 days. Disease authorization, if any later, would not be an anti-aging authorization.
Clinical trials to watch
Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Registered as a disease study, not as a longevity trial.
The future
The open questions are measurement, safety and whether a change in a marker changes how people function. Those are research questions, not results.
Sources
Evidence grades stay in the Longevity Explorer. A disease study is not an anti-aging approval. Explorer
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.